* Besponsa (inotuzumab ozogamicin
) from Pfizer is an anti-body-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
However, the use of ADCs for cancer therapy has achieved considerable success in recent years after the introduction of four clinically approved ADCs such as Brentuximab vedotin (6,7), Trastuzumab emtansine (8-11), Inotuzumab ozogamicin
(12) and Gemtuzumab ozogamicin (12,13) used for the treatment of patients with lymphoma (HL and ALL), HER2-positive, CD22-positive AML and CD33-positive ALL cancers, respectively.
Another anitobody-drug conjugate which was also approved earlier this year is, Besponsa (Inotuzumab Ozogamicin
M2 PHARMA-August 23, 2017-Pfizer Selects Biologics to be Specialty Pharmacy Provider for Besponsa (inotuzumab ozogamicin
) IV Therapy for Adult Relapsed or Refractory B-cell Precursor ALL
The US Food and Drug Administration (FDA) has granted approval to United States-based Pfizer for its Besponsa (inotuzumab ozogamicin
) intended to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), it was reported on Friday.
for inotuzumab ozogamicin
and granted it priority review.
TEHRAN (FNA)- In a randomized Phase III study of the drug inotuzumab ozogamicin
, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
(CMC-544) is an antibody-drug conjugate composed of a humanized anti-CD22 antibody linked to calicheamicin, a potent cytotoxic agent .
Healthcare company Pfizer Inc (NYSE:PFE) reported on Thursday the receipt of approval from the US Food and Drug Administration for Besponsa (inotuzumab ozogamicin
) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).